![Benjamin Kreitman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Benjamin Kreitman
Director/Miembro de la Junta en HAYA Therapeutics SA .
Perfil
Benjamin Kreitman is currently the Director at HAYA Therapeutics SA and the Principal at Broadview Ventures, Inc. He previously worked as the Director at Kantum Pharma, Inc. and as a Consultant at Monitor Deloitte.
He completed his undergraduate degree at The Trustees of Columbia University in The City of New York.
Cargos activos de Benjamin Kreitman
Empresas | Cargo | Inicio |
---|---|---|
Broadview Ventures, Inc.
![]() Broadview Ventures, Inc. Investment ManagersFinance Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts. | Inversor de Capital Privado | 01/01/2021 |
HAYA Therapeutics SA
![]() HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Benjamin Kreitman.
Empresas | Cargo | Fin |
---|---|---|
Monitor Deloitte
![]() Monitor Deloitte Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Monitor Deloitte is a company that provides strategic consulting services. The company is based in Rosslyn, VA. The company was founded by Lene S Schulze. | Consultor / Asesor | - |
Kantum Pharma, Inc.
![]() Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Director/Miembro de la Junta | - |
Formación de Benjamin Kreitman.
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Broadview Ventures, Inc.
![]() Broadview Ventures, Inc. Investment ManagersFinance Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts. | Finance |
Monitor Deloitte
![]() Monitor Deloitte Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Monitor Deloitte is a company that provides strategic consulting services. The company is based in Rosslyn, VA. The company was founded by Lene S Schulze. | Commercial Services |
Kantum Pharma, Inc.
![]() Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
HAYA Therapeutics SA
![]() HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Benjamin Kreitman